Information  X 
Enter a valid email address

IQ-AI Limited (IQAI)

  Print      Mail a friend

Thursday 09 January, 2020

IQ-AI Limited

Imaging Biometrics Partners with AI Metrics

RNS Number : 2041Z
IQ-AI Limited
09 January 2020


("IQ-AI" or the "Company")

Imaging Biometrics Partners with AI Metrics

Imaging Biometrics®, LLC ("IB"), a subsidiary of IQ-AI Limited (LON:IQAI), announced today that is has entered into a global distribution agreement with AI Metrics, LLC (Birmingham, AL). The agreement grants IB non-exclusive global rights to market and distribute AI Metrics' LSN image analysis product. LSN is a first-to-market platform designed by AI Metrics as a virtual liver biopsy, evaluating liver surface nodularity (LSN) to assess Chronic Liver Disease (CLD) using commonly acquired CT images.


Leading up to this agreement, IB assisted AI Metrics in the development of the LSN software by working closely with AI Metrics' CEO, Dr. Andrew Smith, MD, who provided valuable feedback and enhancement suggestions to IB's development team. IB also offered its regulatory expertise and is assisting AI Metrics in obtaining CE Mark and FDA 510(k) market clearance in Europe and the U.S., respectively.


"We are excited about partnering with Imaging Biometrics as we introduce LSN technology to the worldwide market," said Dr. Andrew Smith, CEO of AI Metrics. "Their development efforts have been integral to bringing LSN from promising research to commercial introduction, and the continuity of our relationship moving forward will ensure that LSN can quickly gain rapid and widespread utilization."


Chronic liver disease (CLD) is a serious condition that includes inflammation, progressive stages of fibrosis, and cirrhosis. Clinically silent, over 20 million deaths worldwide are attributed to CLD with the majority of those resulting from non-alcoholic fatty liver disease. AI Metrics has developed its proprietary LSN Software to non-invasively assess the nodules, or bumps, on the liver's surface. This information, when used by trained clinicians, may aid in the diagnosis and staging of CLD.


Currently, clinicians assess patient liver condition via surgical biopsy, which is prone to sampling error, pain, bleeding, and other complications. In contrast, LSN analysis uses common CT scanning technology and proprietary software for accurate, low risk assessment of CLD. While other non-invasive imaging approaches are available, such as magnetic resonance elastography and ultrasound elastography, both require non-standard imaging technology, and patient fasting beforehand.


"LSN fits perfectly with IB's product portfolio and we look forward to helping deploy LSN worldwide," said Michael Schmainda, Director of IB. "The ability to non-invasively and accurately assess CLD is exciting for clinicians and will ultimately benefit patients," Schmainda added.

The Directors of the Company accept responsibility for the contents of this announcement.





For further information, please contact:

IQ-AI Limited

Trevor Brown/Vinod Kaushal/Qu Li

Tel: 020 7469 0930

Peterhouse Capital Limited (Financial Adviser and Broker)

Lucy Williams/Heena Karani

Tel: 020 7220 9797



About AI Metrics

AI Metrics is an early stage company creating transformational image analysis technology that positions radiologists to be the most efficient, valuable clinicians in the patient care continuum.  Founded by emerging radiology leader Dr. Andrew Smith, the Company is developing AI-driven innovations to enhance workflow speed and reduce costs, while improving data quality for clinical and research efforts, and ultimately, for improved physician collaboration and patient care and communication.  For more information about AI Metrics, visit the company's website at


About Imaging Biometrics

Imaging Biometrics, a subsidiary of IQ-AI Limited (LON:IQAI), develops and provides visualization and analytical solutions that enable clinicians to better diagnose and treat diseases with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualization software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company's website at

About IQ-AI
IQ-AI Limited (Ticker:IQAI) is the parent company of Imaging Biometrics® focused on advanced and state of the art medical software and services
. (


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t